Navigation Links
MiMedx Group Announces Post-split Name Change
Date:4/1/2008

TAMPA, Fla., April 1, 2008 /PRNewswire-FirstCall/ -- MiMedx Group, Inc. (OTC Bulletin Board: MDXG), formerly known as Alynx, Co. (OTC Bulletin Board: AYXC), today reported that the contemplated reverse stock split and the redomestication from Nevada to Florida and related name change, to MiMedx Group, Inc., was approved at the shareholders' meeting held March 31, 2008. As a result of the reverse split and redomestication, each former share of Alynx, Co. common stock was converted into approximately 0.3234758 shares of MiMedx Group, Inc. common stock. As a result of the reverse split, there are approximately 36.5 million shares of Common Stock issued and outstanding and an additional 5.3 million shares of Common Stock reserved for issuance for outstanding options and warrants.

Tom D'Alonzo, Chief Executive Officer of MiMedx Group, Inc. stated: "We are pleased to have completed the second stage of this project. Our shares will begin trading under the new symbol 'MDXG.OB' on April 2, 2008."

As a result of the reverse split and redomestication, former holders of MiMedx, Inc. capital stock now hold a number of shares of MiMedx Group, Inc. common stock equal to the number of shares that they held in MiMedx, Inc. prior to the reverse merger transaction with Alynx, Co., which closed February 8, 2008.

About MiMedx Group, Inc.

Founded in 2006, MiMedx Group, Inc. is the parent company for MiMedx, Inc., a development-stage Florida corporation with technology focusing on biomaterials for soft tissue repair, such as tendons, ligaments and cartilage, as well as other biomaterial-based products for other medical applications. MiMedx, Inc., based in Tampa, Florida, holds an exclusive, worldwide license from the Shriner's Hospital for Children and the University of South Florida Research Foundation for certain nordihydroguaiaretic acid (NDGA) technology. MiMedx is targeting this proprietary technology for a number of diverse medical applications. MiMedx, Inc. also has a wholly-owned subsidiary, SpineMedica, LLC, based in Atlanta, Georgia, led by an industry veteran, R. Lewis Bennett. SpineMedica, a Florida limited liability company, is a development-stage company focusing on the commercialization of medical device technologies for application in the spine and chronic back pain. SpineMedica's goal is to acquire promising technologies in this field through licensing arrangements and develop and commercialize such technologies.

For further information, please refer to the Current Report on Form 8-K to be filed by MiMedx Group, Inc. with the SEC as soon as practicable and the Proxy Statement on Schedule14A filed by Alynx, Co. with the SEC on March 10, 2008, accessible at: http://www.sec.gov/edgar/searchedgar/companysearch.html . You may also contact Matthew J. Miller, Executive Vice President of MiMedx Group, at 813-866-0000, for additional information.

This press release contains certain statements that may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Such statements may be identified by their use of terms or phrases such as "expects," "estimates," "projects," "believes," "anticipates," "plans," "intends," and similar terms and phrases. Forward-looking statements are based upon the current beliefs and expectations of our management and are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, which could cause future events and actual results to differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. For example, MiMedx and SpineMedica may be unable to continue their efforts on particular products due to future laboratory results. We disclaim any obligation to update or revise any forward-looking statements to reflect actual results or changes in the factors affecting the forward-looking information.


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alynx, Co. Completes Merger With Medical Device Company MiMedx, Inc.
2. MiMedx Announces Brian J. Splan as President
3. Avicena Group to Present at Noble Financial Conference
4. Chrome Group to Seek Listing for Some of its Subsidiaries
5. Dr. Amit Dhawan Promoted to Medical Director for The Mattson Jack Group
6. Reed Group to Provide MDA Internet Disability Duration Guidelines to U.S. Navy
7. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
8. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
9. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Completion of $2,277,000 Equity Financing
10. ThirdBiotech Networking Group Launches
11. Millennium Biotechnologies Group, Inc. (MBTG.OB) Announces Appointment of Mark C. Mirken as its President and Chief Operating Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017  Aethlon Medical, Inc. (Nasdaq: ... by its Chairman and CEO, Jim Joyce . ... Security Conference last Saturday, Bill Gates warned ... more people than nuclear weapons. Mr. Gates expressed his ... intelligence agencies, that scientific terrorists have access to the ...
(Date:2/24/2017)... Staten Island, NY (PRWEB) , ... February 24, 2017 , ... ... exponential rate. Founded in late 2014, FireflySci had the goal of bringing their ... 2017, that goal continues to shape the path that FireflySci is going on as ...
(Date:2/23/2017)... and NEW YORK ... HIMSS, Lumeon , a leading digital health ... Telehealth), a provider of telemedicine and remote patient ... pathways for telemedicine reimbursements.  DN ... their patients, in real-time, extending consultations beyond a ...
(Date:2/23/2017)... JOSE, Calif. , Feb. 23, 2017 /PRNewswire/ ... exclusive license for two key immunotherapy technologies from ... first technology provides a method to monitor a ... such as PD-L1 and CTLA-4.  The second license ... if a patient is likely to have an ...
Breaking Biology Technology:
(Date:2/9/2017)... 2017 The biomass boiler market report by ... boiler market globally in terms of revenue (US$ Mn) ... market for biomass boilers has been segmented on the ... country/region. The market based on feedstock type, has been ... & energy crops, urban residues, and others. On the ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global ... reach $11.4 billion by 2021, growing at a compound annual ... - An overview of the global markets for synthetic biology. ... estimates for 2016, and projections of compound annual growth rates ...
(Date:2/7/2017)... --  MedNet Solutions , an innovative SaaS-based eClinical technology ... is pleased to announce that the latest release of ... and award winning eClinical solution, is now available for ... a proven Software-as-a-Service (SaaS) clinical research technology platform that ... delivers an entire suite of eClinical tools to support ...
Breaking Biology News(10 mins):